Antibodies to SARS-CoV-2 and risk of future sickness
Joakim Dillner(Karolinska University Hospital), Kalle Conneryd Lundgren(Karolinska University Hospital), Eni Andersson(Science for Life Laboratory), Laila Sara Arroyo Mühr(Karolinska University Hospital), Jennie Olofsson(Science for Life Laboratory), Jonas Blomqvist(Karolinska University Hospital), Anna Månberg(Science for Life Laboratory), My Hedhammar(KTH Royal Institute of Technology), Elisa Pin(KTH Royal Institute of Technology), Sophia Hober(KTH Royal Institute of Technology), Camilla Lagheden(Karolinska Institutet), Carina Eklund(Karolinska Institutet), August Jernbom Falk(Science for Life Laboratory), Miriam Elfström(Karolinska University Hospital), Peter Nilsson(Science for Life Laboratory), Sofia Bergström(Science for Life Laboratory), Emilie Hultin(Karolinska University Hospital), Cecilia Hellström(Science for Life Laboratory), Johan Mattsson(Karolinska University Hospital), Sara Nordqvist Kleppe(Karolinska Institutet)
Cited by 3
Related Papers
A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types
|Virology|2013|317
Epigenome-based cancer risk prediction: rationale, opportunities and challenges
|Nature Reviews Clinical Oncology|2018|173
Integration of molecular profiles in a longitudinal wellness profiling cohort
|Nature Communications|2020|151